Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials

被引：0
作者：
Kyaw Zin Thein
Thura Win Htut
Somedeb Ball
Sriman Swarup
Anita Sultan
Thein Hlaing Oo
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Investigational Cancer Therapeutics
[2] University of Aberdeen,Department of Hematology, Aberdeen Royal Infirmary Hospital
[3] Texas Tech University Health Sciences Center,Department of Internal Medicine
[4] Texas Tech University Health Sciences Center,Department of Hematology/Oncology
[5] The University of Texas MD Anderson Cancer Center,Section of Benign Hematology
来源：
Breast Cancer Research and Treatment | 2020年 / 183卷
关键词：
Metastatic breast cancer; Venous thromboembolism; Hormone receptor-positive HER2-negative; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：479 / 487
页数：8
相关论文
共 50 条
  • [21] The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early + /HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials
    Keskinkilic, Merve
    Arayici, Mehmet Emin
    Basbinar, Yasemin
    Ellidokuz, Hulya
    Yavuzsen, Tugba
    Oztop, Ilhan
    BREAST, 2024, 78
  • [22] Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
    Piezzo, Michela
    Chiodini, Paolo
    Riemma, Maria
    Cocco, Stefania
    Caputo, Roberta
    Cianniello, Daniela
    Di Gioia, Germira
    Di Lauro, Vincenzo
    Rella, Francesca Di
    Fusco, Giuseppina
    Iodice, Giovanni
    Nuzzo, Francesco
    Pacilio, Carmen
    Pensabene, Matilde
    Laurentiis, Michelino De
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (17) : 1 - 17
  • [23] Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
    Yuan Yang
    Zhang Shaohua
    Wang Tao
    Bian Li
    Yan Min
    Yin Yongmei
    Song Yuhua
    Wen Yi
    Li Jianbin
    Jiang Zefei
    中华医学杂志英文版, 2023, 136 (12)
  • [24] Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials
    Omarini, Claudia
    Piacentini, Federico
    Sperduti, Isabella
    Barbolini, Monica
    Isca, Chrystel
    Toss, Angela
    Cortesi, Laura
    Barbieri, Elena
    Dominici, Massimo
    Moscetti, Luca
    BMC CANCER, 2020, 20 (01)
  • [25] Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis
    Salvo, Elizabeth M.
    Ramirez, Abril Oliva
    Cueto, Jenilee
    Law, Ernest H.
    Situ, Aaron
    Cameron, Chris
    Samjoo, Imtiaz A.
    BREAST, 2021, 57 : 5 - 17
  • [26] Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials
    Claudia Omarini
    Federico Piacentini
    Isabella Sperduti
    Monica Barbolini
    Chrystel Isca
    Angela Toss
    Laura Cortesi
    Elena Barbieri
    Massimo Dominici
    Luca Moscetti
    BMC Cancer, 20
  • [27] mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials
    Rotundo, Maria Saveria
    Galeano, Teresa
    Tassone, Pierfrancesco
    Tagliaferri, Pierosandro
    ONCOTARGET, 2016, 7 (19) : 27055 - 27066
  • [28] Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors
    Pathak, Neha
    Mittal, Abhenil
    Kumar, Sudhir
    Nagpal, Chitrakshi
    Amir, Eitan
    Haldar, Partha
    Gangadharaiah, Bharath B.
    Kumar, Akash
    Mishra, Ashutosh
    Batra, Atul
    CURRENT ONCOLOGY, 2025, 32 (01)
  • [29] Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials
    Wen-Zhao Lin
    Qi-Ni Xu
    Hong-Biao Wang
    Xu-Yuan Li
    Breast Cancer, 2017, 24 : 345 - 352
  • [30] Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials
    Lin, Wen-Zhao
    Xu, Qi-Ni
    Wang, Hong-Biao
    Li, Xu-Yuan
    BREAST CANCER, 2017, 24 (03) : 345 - 352
12345